profit from every $100 of sales.
$0$100
Oramed Pharmaceuticals
$4.03-2.42% today
+63.2% in 1 year
1-year low $2.331-year high $5.34
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $2.58 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Oramed Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $2.70 million in 2022 to $2.00 million in 2025, with $64.1 million of profit last year.
SalesProfit
Oramed Pharmaceuticals vs. similar companies
Oramed Pharmaceuticals grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Oramed Pharmaceuticals | 2.6× · Cheap | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Oramed Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3 | 1 | 0 | 2 | |
| – | – | 0 | 0 | |
| -41 | -16 | -13 | -15 | |
| -38 | 7 | -15 | 75 | |
| -37 | 6 | -19 | 64 | |
| -0.94 | 0.14 | -0.48 | 1.50 | |
| – | – | – | 0.7% | |
| -1,502.0% | -1,176.8% | – | -754.4% | |
| -1,352.6% | 412.3% | – | 3,202.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 162 | 221 | 155 | 231 |
| Cash | 40 | 9 | 54 | 46 |
| Total debt | 1 | 52 | 0 | 1 |
| Total liabilities | 10 | 58 | 10 | 31 |
| 152 | 164 | 146 | 200 | |
| 39 | 41 | 41 | 42 | |
| -19.5% | 2.6% | -8.1% | 29.7% | |
| -24.1% | 3.4% | -13.0% | 32.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -28 | -10 | -8 | -9 | |
| 0 | 0 | 0 | 2 | |
| -28 | -11 | -8 | -11 | |
| Dividends paid | – | – | – | – |
| – | 0 | 2 | 5 | |
| 12 | 4 | 4 | 6 |
Valuation
- 2.6×
- –
- –
- 0.8×
- 82.5×
- –
- 1.6×
- -6.7%
- 38.8%
- 6.1%
Profitability
- 0.7%
- -754.4%
- 3,202.5%
- -754.4%
- -19.1%
- -3.4%
- 43.1%
- 77.2%
- -19.2%
- 319.1%
Growth
- −9.6%
- –
- −8.6%
- –
- +9.8%
Financial health
- 3.0×
- 0.00
- 0.8%
- –
- 6.98
- 6.98
- 0.02
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 22%of 952
Top 1%of 576
Bottom 7%of 870
Bottom 15%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 31, 2026 | 0.94 | – | – |
| Mar 26, 2026 | -0.06 | -0.08 | +25.0% |
| Nov 13, 2025 | 1.13 | -0.04 | +2,925.0% |
| Aug 14, 2025 | -0.05 | -0.04 | −25.0% |
| May 15, 2025 | -0.19 | -0.03 | −533.3% |
| Mar 27, 2025 | 0.01 | -0.03 | +133.3% |
| Nov 7, 2024 | -0.48 | -0.00 | −9,695.9% |
| Aug 14, 2024 | 0.26 | 0.01 | +2,500.0% |
6.1%of the share price, paid each year
On $1,000 invested$61a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
14.4% of its profit
Room to growStretchedMore than it earnsNews
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
84Pass
Philip Fisher
29No pass
Peter Lynch
42No pass
Joel Greenblatt
62Pass
Charlie Munger
21No pass
Terry Smith
15No pass
Questions about Oramed Pharmaceuticals
Is Oramed Pharmaceuticals a good stock to buy?
A strong, very profitable business, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Oramed Pharmaceuticals AI analysis
What does Oramed Pharmaceuticals do?
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. It is in Biotechnology.
Does Oramed Pharmaceuticals pay a dividend?
Yes. At today's price the dividend is 6.1% a year, about 14% of its yearly profit.
Is Oramed Pharmaceuticals stock halal?
Questionable. Oramed Pharmaceuticals sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Oramed Pharmaceuticals stock done over the past year?
Up 63.2% over the past twelve months, to $4.03. It traded between $2.33 and $5.34 and is 24.5% below its high.
Who are Oramed Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Oramed Pharmaceuticals's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.